Trulicity (Dulaglutide) Insurance Denial Appeal Guide

Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. While it's been widely covered, formulary changes favoring newer agents like Mounjaro or Ozempic may lead to denials or non-preferred status.

Common Denial Reasons

  • Formulary shift to preferred GLP-1 alternatives
  • Step therapy (metformin → sulfonylurea → then GLP-1)
  • Prior authorization requirements
  • Quantity limits

Clinical Advantages for Appeals

  • REWIND trial: cardiovascular outcome benefit
  • Once-weekly dosing (convenience, adherence)
  • Proven HbA1c reduction (1.0-1.5% average)
  • Weight loss benefit (averaging 3-5 kg)
  • Ready-to-use pen (no mixing required)

Appeal Strategy

  1. ADA Standards of Care support for GLP-1 therapy
  2. Document metformin intolerance or failure if applicable
  3. REWIND cardiovascular data for patients with CVD risk
  4. Endocrinologist recommendation
  5. If switching from another GLP-1, document why Trulicity is preferred

Need Help Writing Your Appeal?

Our AI-powered tool analyzes your denial letter and generates a personalized appeal in minutes. Upload your denial and get started for free.

Start Your Free Appeal

Frequently Asked Questions

Is Trulicity being discontinued?

Trulicity is not being discontinued. However, some insurers have moved it to non-preferred tiers as newer GLP-1 agonists (Ozempic, Mounjaro) have entered the market. If your plan no longer covers Trulicity at a preferred level, you can appeal or request an exception.

Related Resources